Dolca Thomas

Dr. Thomas is a Venture Partner at Samsara BioCapital and an independent director at Chinook Therapeutics. She served as the Executive Vice President, Head of Research and Development and Chief Medical Officer at Equillium from January 2021 through February 2022. Previously, she served as Principia’s Chief Medical Officer from 2018 until its acqusition by Sanofi in September 2020. Prior to Principia, Dr. Thomas was Vice President and Global Head of Translational Medicine for Immunology, Inflammation, and Infectious Disease at Roche; Vice President of Clinical Development and Clinical Immunophenotyping at Pfizer and Vice President and Chief Development Officer of the Biosimilars Research and Development Unit at Pfizer. Dr. Thomas began her industry career at Bristol-Myers Squibb as Director of Global Clinical Development in Immunology, where she was involved in late stage clinical drug development including the approval of the immunomodulatory drug, Belatacept.

Prior to her career in drug development, Dr. Thomas was a tenured track faculty member at Weill Cornell Medicine’s Department of Nephrology and Transplantation Medicine. Dr. Thomas received a B.A. in sociology and a M.D. from Cornell University. Dr. Thomas resides in the San Francisco, Bay Area in California.